Crinetics Pharmaceuticals, Inc.
NASDAQ:CRNX
50.49 (USD) • At close January 6, 2025
Overview | Financials
Numbers are in millions (except for per share data and ratios) USD.
| 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | |
|---|---|---|---|---|---|---|---|---|
| Assets: | ||||||||
| Current Assets: | ||||||||
| Cash & Cash Equivalents
| 54.897 | 32.672 | 200.695 | 93.087 | 40.326 | 44.973 | 14.192 | 12.152 |
| Short Term Investments
| 503.658 | 301.753 | 133.012 | 77.793 | 78.066 | 118.902 | 0 | 0 |
| Cash and Short Term Investments
| 558.555 | 334.425 | 333.707 | 170.88 | 118.392 | 163.875 | 14.192 | 12.152 |
| Net Receivables
| 9.351 | 0 | 2.029 | 1.833 | 0 | 0 | 0.734 | 0.072 |
| Inventory
| 0 | 0 | 8.072 | -1.833 | -1.378 | 0 | 0.141 | 0.098 |
| Other Current Assets
| 6.247 | 10.759 | 8.072 | 4.779 | 1.316 | 0.876 | 0.239 | 0.043 |
| Total Current Assets
| 574.153 | 345.184 | 344.72 | 177.492 | 123.339 | 166.683 | 15.165 | 12.365 |
| Non-Current Assets: | ||||||||
| Property, Plant & Equipment, Net
| 57.43 | 4.986 | 4.717 | 5.413 | 6.456 | 4.232 | 0.4 | 0.224 |
| Goodwill
| 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Intangible Assets
| 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Goodwill and Intangible Assets
| 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Long Term Investments
| 1.77 | 1.969 | 1.01 | 0.5 | 0.5 | 0.5 | 0 | 0 |
| Tax Assets
| 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Other Non-Current Assets
| 2 | 0.037 | 0.568 | 0.04 | 0.082 | 0 | 0.033 | 0.01 |
| Total Non-Current Assets
| 61.2 | 6.992 | 6.295 | 5.953 | 7.038 | 4.732 | 0.433 | 0.234 |
| Total Assets
| 635.353 | 352.176 | 351.015 | 183.445 | 130.377 | 171.415 | 15.598 | 12.599 |
| Liabilities & Equity: | ||||||||
| Current Liabilities: | ||||||||
| Account Payables
| 6.548 | 6.883 | 3.422 | 3.488 | 2.698 | 1.456 | 0.403 | 0.34 |
| Short Term Debt
| 4.173 | 1.051 | 0 | 0 | 0 | 0 | 0 | 0.049 |
| Tax Payables
| 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Deferred Revenue
| 2.056 | 2.24 | -0.939 | -0.835 | -0.724 | 0 | 0 | 0 |
| Other Current Liabilities
| 31.165 | 17.549 | 12.573 | 7.001 | 5.642 | 6.469 | 0.494 | 0.501 |
| Total Current Liabilities
| 43.942 | 27.723 | 15.995 | 10.489 | 8.34 | 7.925 | 0.897 | 0.89 |
| Non-Current Liabilities: | ||||||||
| Long Term Debt
| 47.555 | 2.024 | 3.074 | 4.014 | 4.849 | 0 | 0 | 0.163 |
| Deferred Revenue Non-Current
| 4.75 | 6.101 | 0 | 0 | 0 | 0 | 0 | 0 |
| Deferred Tax Liabilities Non-Current
| 0 | -6.101 | 0 | 0 | 0 | 0 | 0 | 0 |
| Other Non-Current Liabilities
| 0 | 0 | 0.002 | 0.023 | 0.049 | 3.265 | 29.723 | 17.75 |
| Total Non-Current Liabilities
| 52.305 | 8.125 | 3.076 | 4.037 | 4.898 | 3.265 | 29.723 | 17.913 |
| Total Liabilities
| 96.247 | 35.848 | 19.071 | 14.526 | 13.238 | 11.19 | 30.62 | 18.803 |
| Equity: | ||||||||
| Preferred Stock
| 0 | 0 | 0 | 0 | 0 | 171.415 | 29.7 | 17.74 |
| Common Stock
| 1,191.831 | 759.432 | 607.581 | 336.508 | 210.793 | 0.024 | 0.001 | 0.001 |
| Retained Earnings
| -653.702 | -439.173 | -275.255 | -167.614 | -93.802 | -43.38 | -16.265 | -7.108 |
| Accumulated Other Comprehensive Income/Loss
| 0.977 | -3.931 | -0.382 | 0.025 | 0.148 | 0.061 | -0.304 | -0.182 |
| Other Total Stockholders Equity
| 0 | 0 | 0 | 0 | 0 | -342.83 | 1.546 | 1.085 |
| Total Shareholders Equity
| 539.106 | -439.173 | -275.255 | -167.614 | -93.802 | -43.38 | -15.022 | -6.204 |
| Total Equity
| 539.106 | -439.173 | -275.255 | -167.614 | -93.802 | -43.38 | -15.022 | -6.204 |
| Total Liabilities & Shareholders Equity
| 635.353 | -403.325 | -256.184 | -153.088 | -80.564 | -32.19 | 15.598 | 12.599 |